LY2940680 + carboplatin + etoposide

This is a three-drug combination therapy of **LY2940680** (taladegib), an oral small molecule inhibitor targeting the hedgehog signaling pathway via smoothened (SMO) antagonism, plus **carboplatin** and **etoposide**, two established cytotoxic chemotherapy agents. LY2940680 acts as a **smoothened (SMO) antagonist**, disrupting the hedgehog signaling pathway and thus inhibiting tumor growth in hedgehog-pathway dependent cancers. **Carboplatin** is a platinum-based chemotherapy agent that cross-links DNA, leading to apoptosis, and **etoposide** is a topoisomerase II inhibitor that causes DNA strand breaks and apoptosis. This combination has been investigated in clinical trials, particularly for small cell lung cancer and other advanced malignancies, aiming to enhance antitumor activity by combining targeted pathway inhibition with DNA-damaging chemotherapy[1][3][9].